This will likely include the more thorough investigation of SGLT2 inhibitors and GLP1 receptor agonists, which show effective clinical outcomes not only in reducing blood glucose levels, but also in alleviating the diabetic complications particularly in cardiovascular system and kidney.[216, 217] Furthermore, the clinical validation of uni‐molecular, dual agonists, islet cell replacement as well as novel RNA‐based therapies for tailored diabetes treatment will certainly contribute to more efficacious therapies in type 2 diabetes and related complications. This evidence concerns the gene SLC5A2 and diabetes mellitus.